Abstract
This paper examines the opportunities and challenges pharmaceutical companies encounter when considering entry into the niche US veterinary generics market. The key points compare the growth of the companion animal market as an attractive lure for potential entrants, to the regulatory hurdles of drug approval, drug distribution and veterinarian relationships and education that could dissuade companies from testing the waters of veterinary generics.
Keywords
Get full access to this article
View all access options for this article.
